At a glance
ClinicalIndex Comparison RecordN/ACompleted· 104 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Description of the Effectiveness and Tolerability of аgomelatine in the Treatment of Patients With Depression Occurred After SARS-CoV-2 Infection in the Daily Clinical Practice in Russia (TELESPHOR)
In Brief
An observational study for Depression and COVID-19. Completed, enrolled 104 participants across 1 site.
Detailed Summary
This is a multi-centre, observational, non-interventional study, which will prospectively collect clinical and socio-demographic data from patients with depression occurred after COVID 19 in real clinical settings during 8 weeks of treatment. 10 clinics and 10 of psychiatrists and neurologists across the country will participate in the study and it is estimated that each investigating physician will enroll 10 patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, COVID-19
CountriesRussia
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
First PostedApr 2022
Enrollment StartApr 2022
Primary CompletionFeb 2023
Study CompletionMar 2023
TodayJul 2026
First PostedApr 12, 2022
Enrollment StartApr 19, 2022
Primary CompletionFeb 20, 2023
Study CompletionMar 15, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 4.2 years ago